A board member and the largest investor in Durham-based Dova Pharmaceuticals Inc. has purchased another $576,000 worth of stock in the company, according to a filing with the Securities and Exchange Commission.

Paul B. Manning purchased the shares in transactions on Aug. 15 and Aug. 16 in prices ranging from $21.16 to $26.81 per share.

He now owns 125,870 shares in the drug development company worth nearly $3.4 million.

Manning, who is based in Charlottesville, Virginia, operates PBM Capital Investments, which also owns 12.2 million shares of Dova Pharmaceuticals worth more than $325 million.

Earlier this month, Dova reported a second quarter loss that missed Wall Street expectations in its first quarter as a public company.

Dova went public in late June. The company was formed in March 2016 and has produced no revenue. It posted a loss of $27.2 million in 2016 and a loss of $5.4 million in the first three months of 2017.

Dova is developing treatments for patients suffering from orphan diseases.

The company’s lead investigational drug, avatrombopag, is in the process of completing two Phase 3 clinical trials researching its use as a potential treatment for thrombocytopenia in patients with chronic liver disease.

The company plans to file a new drug application with the U.S. Food and Drug Administration for avatrombopag in the third quarter of 2017.